Mohamed Elmeliegy1,2, Jason Den Haese3,4, Chetasi Talati3,5, Meir Wetzler3, William J Jusko6. 1. Pfizer, Inc., 10555 Science Center Dr., San Diego, CA, 92121, USA. Mohamed.Elmeliegy@pfizer.com. 2. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, USA. Mohamed.Elmeliegy@pfizer.com. 3. Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA. 4. Department of Biology and Mathematics, D'Youville College, Buffalo, NY, USA. 5. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA. 6. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, USA.
Abstract
BACKGROUND: AML patients with FLT3/ITD mutations have poor response to cytarabine-based chemotherapy. FLT3 inhibitors (FLT3i) may resensitize cells to cytarabine (CYT). Improving treatment outcome of this combination may benefit from a mechanistic extrapolation approach from in vitro data. METHODS: The effects of CYT and several FLT3i on cell proliferation and cell cycle kinetics were examined in AML cell lines. The effect of FLT3i (quizartinib, midostaurin, sorafenib) on cell proliferation and cell cycle kinetics was assessed in AML cell lines with differing FLT3 status; HEL (negligible expression of wild-type FLT3), EOL1 (wild-type FLT3), MV4-11 (FLT3-ITD resulting in constitutively active isoform). Semi-mechanistic cell cycle models for CYT and FLT3i were developed. Clinical CYT and quizartinib pharmacokinetic dosage regimens were modeled. Survival of AML patients was described via a hazard model. Simulations exploring different CYT/quizartinib regimens were conducted with the goal of improving treatment outcome. RESULTS: FLT3 status was associated with sensitivity to CYT (HEL cells most sensitive > EOL1 > MV4-11 cells). This order of sensitivity is reversed for FLT3i. Cytarabine induced apoptosis in the S-phase while all FLT3i induced apoptosis and cell cycle arrest at G1 phase. Simulations of candidate clinical regimens predict better cell kill upon adding quizartinib simultaneously with or immediately after CYT exposure. Overall survival was predicted to be significantly better with quizartinib 200 mg administered every 48 h vs every 24 h in patients with FLT3 aberrations. CONCLUSION: Simultaneous administration of quizartinib and CYT every other day is a promising combination regimen for AML patients with FLT3 mutations.
BACKGROUND:AMLpatients with FLT3/ITD mutations have poor response to cytarabine-based chemotherapy. FLT3 inhibitors (FLT3i) may resensitize cells to cytarabine (CYT). Improving treatment outcome of this combination may benefit from a mechanistic extrapolation approach from in vitro data. METHODS: The effects of CYT and several FLT3i on cell proliferation and cell cycle kinetics were examined in AML cell lines. The effect of FLT3i (quizartinib, midostaurin, sorafenib) on cell proliferation and cell cycle kinetics was assessed in AML cell lines with differing FLT3 status; HEL (negligible expression of wild-type FLT3), EOL1 (wild-type FLT3), MV4-11 (FLT3-ITD resulting in constitutively active isoform). Semi-mechanistic cell cycle models for CYT and FLT3i were developed. Clinical CYT and quizartinib pharmacokinetic dosage regimens were modeled. Survival of AMLpatients was described via a hazard model. Simulations exploring different CYT/quizartinib regimens were conducted with the goal of improving treatment outcome. RESULTS:FLT3 status was associated with sensitivity to CYT (HEL cells most sensitive > EOL1 > MV4-11 cells). This order of sensitivity is reversed for FLT3i. Cytarabine induced apoptosis in the S-phase while all FLT3i induced apoptosis and cell cycle arrest at G1 phase. Simulations of candidate clinical regimens predict better cell kill upon adding quizartinib simultaneously with or immediately after CYT exposure. Overall survival was predicted to be significantly better with quizartinib 200 mg administered every 48 h vs every 24 h in patients with FLT3 aberrations. CONCLUSION: Simultaneous administration of quizartinib and CYT every other day is a promising combination regimen for AMLpatients with FLT3 mutations.
Authors: Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria-Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Patrick P Zarrinkar; Ruwanthi N Gunawardane; Merryl D Cramer; Michael F Gardner; Daniel Brigham; Barbara Belli; Mazen W Karaman; Keith W Pratz; Gabriel Pallares; Qi Chao; Kelly G Sprankle; Hitesh K Patel; Mark Levis; Robert C Armstrong; Joyce James; Shripad S Bhagwat Journal: Blood Date: 2009-08-04 Impact factor: 22.113
Authors: Bruce Ruggeri; Jasbir Singh; Diane Gingrich; Thelma Angeles; Mark Albom; Shi Yang; Hong Chang; Candy Robinson; Kathryn Hunter; Pawel Dobrzanski; Susan Jones-Bolin; Sonya Pritchard; Lisa Aimone; Andres Klein-Szanto; Jean-Marc Herbert; Francoise Bono; Paul Schaeffer; Pierre Casellas; Bernard Bourie; Roberto Pili; John Isaacs; Mark Ator; Robert Hudkins; Jeffrey Vaught; John Mallamo; Craig Dionne Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Fatima Baker; Ibrahim H Polat; Khalil Abou-El-Ardat; Islam Alshamleh; Marlyn Thoelken; Daniel Hymon; Andrea Gubas; Sebastian E Koschade; Jonas B Vischedyk; Manuel Kaulich; Harald Schwalbe; Shabnam Shaid; Christian H Brandts Journal: Cancers (Basel) Date: 2021-12-06 Impact factor: 6.639